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ebivolol in Older
dults With Heart Failure
educed Rates for Seniors?*
aul W. Armstrong, MD,† Karen P. Alexander, MD‡
dmonton, Alberta, Canada; and
urham, North Carolina
How old would you be if you didn’t know how old you are?
—Satchel Paige (1)
eart failure constitutes a major growth industry in cardio-
ascular medicine reflecting the convergence of an aging
opulation with lifesaving pharmacologic, electrical, and
echanical interventions (2). Although age is well recog-
ized as one of the most powerful risk factors for morbid
nd mortal events, the treatment–risk paradox characterized
y under-use of effective therapies in this population is
triking (3). Because this paradox seems related to the lack
f an evidence base in the oldest patients, the SENIORS
Study of the Effects of Nebivolol Intervention on Out-
omes and Rehospitalization in Seniors with Heart Failure)
rial has been welcome in addressing this gap (4). The
merican Heart Association advocates that prospective
ardiovascular clinical trials enroll the elderly in proportion
o their prevalence among the general treated population to
etter define the balance between benefit and risk (5). Yet,
closer look at the SENIORS trial yields additional insights
nto the treatment–risk paradox in older adults.
See page 2150
The SENIORS trial randomly assigned over 2,000 older
dults (age 70 years) with a history of congestive heart
ailure to beta-blockers irrespective of ejection fraction (EF)
4). Undertaken in both western and eastern Europe, this
tudy was a placebo-controlled trial of a third-generation
eta-1-selective blocker, nebivolol. This agent has vasodi-
ating properties attributed to nitric oxide modulation
hought to be potentially advantageous in patients with
iastolic dysfunction and heart failure (6). The trial con-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiology, Department of Medicine, University of Alberta,m
dmonton, Alberta, Canada; and the ‡Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina.luded enrollment in December 2002 with a 21-month
ollow-up and showed a 14% reduction (vs. projected 25%
eduction) in the primary composite end point of mortality and
ardiovascular hospital readmission from the placebo rate of
5.3%. No influence was evident from subgroup analysis by
ge, sex, or EF. However, intriguing trends were noted toward
ess benefit in older adults and more benefit in those with
educed EF and in female subjects (interaction term p 0.11).
Based on the primary SENIORS report, the 2008 Euro-
ean Society of Cardiology Heart Failure guidelines now
nclude nebivolol with the other 3 standard beta-blockers as
Class 1A recommendation in symptomatic heart failure
ith a left ventricular (LV) EF 40% (7). In this issue of
he Journal, 4 years after their primary report, the SE-
IORS trial investigators further evaluate the relative
fficacy of nebivolol therapy on patients with diminished
ersus preserved (relatively) EF (35%) (8). About one-
hird versus the originally projected one-half of patients had
reserved LV function. As previously reported, the modest
reatment benefit was equally applicable to those with
iminished versus those with preserved EF. When results
ere further explored as a continuous variable as well as
cross 4 EF subgroups between 30% and 46%, no
ignificant interaction between treatment effect and EF was
een.
Does the current study add to our understanding of the
echanism of benefit attributable to nebivolol across differ-
ng baseline EFs? Clearly the agent had a larger effect on EF
n patients with a baseline 35% versus those 35%,
lthough the 5-point absolute parallel increase in EF in the
ow-EF placebo group suggests caution in attribution of all
f this change to study drug. A more modest but statistically
ignificant increase in EF was seen with nebivolol in those
ith baseline EFs 35%. Previously a small echocardio-
raphic substudy of the SENIORS trial failed to show any
mprovement in diastolic performance (9). Hence, the
echanism of the benefit attributable to nebivolol in those
ith preserved LV function remains speculative. Benefit
ccruing from a reduction in peripheral vascular resistance,
yocardial ischemia, or cardiac dysrhythmia are all plausible
ut unproven. It should be noted that although the primary
utcome composite effect was similar in low and preserved
F groups, there was only a 1.1% absolute (difference n 
) reduction in all-course mortality in those with EFs35%
ersus a 2.8% (difference n  20) absolute difference for
hose with EFs 35%.
Does the current study enhance understanding of nebivo-
ol’s mechanism of benefit across the spectrum of age? What
otential implications emerge for future studies in the
lderly? In the primary SENIORS report, there was a hint
f an attenuated treatment effect in those above the cohort
edian age of 75.2 years: this was even more marked in the
ery elderly (age 85 years). In general, as risk increases, so
hould the observed benefit of an agent that directly
odifies that risk. Hence the blunting of effect in the oldest
g
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Nebivolol in Older Adults With HF June 9, 2009:2159–61roup, and perhaps also the reduced overall effect in the
ENIORS trial compared with that predicted, deserves
onsideration. First, the benefit of nebivolol use on mortal-
ty in older adults may be attenuated by competing contrib-
tors to death not modifiable by nebivolol. Although the
re-specified component of the primary end point, that is,
ardiovascular hospitalization, was reduced by nebivolol,
ll-cause hospitalization was unchanged. Second, it was only
he highest dose of nebivolol that was associated with event
eduction in the SENIORS trial. During the titration
hase, 7% of patients could not tolerate any nebivolol, and
3% were not at the dose at which mortality benefit was
lear (10). Those unable to tolerate target doses were older
nd were more likely to be receiving other pharmaceuticals
hat alter heart rate and conduction (antiarrhythmic agents
nd calcium blockers). This underscores the challenges of
he generalizability of this trial to older adults in clinical
ractice, where polypharmacy, pre-existing frailty, and con-
itions affecting tolerability of beta-blockers in maximal
oses are more prevalent. Lastly, in older adults, functional
utcomes are at least equally as important as mortality
enefits. Unfortunately and surprisingly, the pre-specified
econdary outcomes of functional capacity by New York
eart Association functional class and 6-min walk test in
he SENIORS trial have never been reported: these data
ould greatly assist clinicians in applying the overall result
11). The net clinical benefit incorporating functional and
ortality outcomes to ensure a positive balance from the
chieved dose is the desired end point in this population. It
s therefore likely that patient-centered, evidence-based
edicine operating in the real world explains at least some
f the observed treatment–risk paradox in relation to beta-
lockers in older heart failure patients. Ironically these end
oints are well aligned with Satchel Paige’s sage query (1)
ntroducing this editorial, as well as a recent Class 1B
merican College of Cardiology/American Heart Associa-
ion recommendation articulating that for older patients
Figure 1 Winning Clinical Trial in the Elderly
Starting at the bottom of the figure, the upward thrust incorporates key ele-
ments especially relevant to clinical trial design in older adults with cardiovas-
cular disease.decisions on management . . . should be patient centered,
ith consideration given to general health, functional and
ognitive status, comorbidities, life expectancy and patient
references and goals” (12). We desperately need more and
etter clinical trials in older adults that reflect new under-
tanding of key definition and design issues. Building these
etrics, assessments of variation in older adults using
henotypic and biological constructs, determining relevant
et clinical end points, and understanding the selection of
atients using registries as shown in Figure 1 will help
rovide the answers we urgently need for the future. Seniors
ith heart failure have a reduced rate of beta-blocker usage
nd reduced rates of inclusion in cardiovascular clinical trial
opulations relative to their contribution to the mortality
nd morbidity of the diseases under study. If they have the
ame or a reduced mortality benefit, then it is vitally
mportant to understand what effect new treatments have on
he quality of their remaining life. The future for seniors is
ow.
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